LIver Forum 19

E-mail Print

Liver Forum 19 — Wednesday, September 10, 2025 — Institut Pasteur, Paris, France

Materials

pdfAgenda
pdfParticipant List 

Introductory Remarks and Program Overview

Welcome, Program Overview, and Acknowledgments
Edyth Dwyer, Forum for Collaborative Research

Opening Remarks
Veronica Miller, Forum for Collaborative Research
Michelle Long, Novo Nordisk
Arun Sanyal, Virginia Commonwealth University

pdfStephen A. Harrison Fellowship Introduction
Elena Samsonova, Fatty Liver Foundation

Session I: Meaningful Patient Engagement in Drug Development: Leading Through Example — Where We Are, and What’s Next

pdfOverview of Patient Engagement in Drug Development: Leading Through Example
Rosemarie Sellati, Regeneron Pharmaceuticals
Michael Betel, Fatty Liver Alliance
Henry Chang*, Fatty Liver Foundation

Panel and Open Discussion
Monica Lizarraga*, Madrigal Pharmaceuticals
Christopher Frates, Madrigal Pharmaceuticals

Session II: Moving Towards Consensus on Pediatric MASH Trial Design

pdfStandardization of Clinical Trial Design for Youth‑Onset MASH
Miriam Vos, Michigan State University
Bryan Rudolph, Boehringer Ingelheim

Open Discussion
All attendees

Session III: Placebo‑Arm Database Updates

pdfMASH Placebo‑Arm Database Project Update – Data Harmonization & Proposed Analyses
Margot Yann*, Forum for Collaborative Research

Open Discussion
All attendees

Session IV: New Developments in Non‑Invasive Testing

pdfThe Cholate Challenge Test Predicts Clinical Outcome and Quantifies Changes in Clinical Risk
Gregory Everson, HepQuant

Open Discussion
All attendees

Session V: Moving Towards Consensus on Non‑Invasive Tests

pdfWhat’s New Since Last Time
Veronica Miller, Forum for Collaborative Research

pdfOverview of the Liver Forum Proposal for a NIT‑based RLSE in MASLD
Quentin Anstee*, Newcastle University

pdfUpdate on Literature Review
Richard Haubrich, Forum for Collaborative Research

Letter of Intent for LSM by VCTE as Reasonably Likely Surrogate Endpoint – Echosens Update
Céline Fournier, Echosens

Panel and Open Discussion
All attendees

Session VI: Moving Towards Consensus on NIT Statistical Approaches

pdfNIT Outcome Measures for MASH Should Reflect Clinical Significance
Alejandro Schuler*, UC Berkeley

Statistics Panel Discussion
Alejandro Schuler*, UC Berkeley
Nancy Obuchowski*, Cleveland Clinic
Yuanyuan Tang*, Eli Lilly and Company
Luiza Borowska, Boehringer Ingelheim

Open Discussion
All attendees

Session VII: Defining Progression to Cirrhosis

pdfMoving from RLSE to a Validated Surrogate Endpoint for MASH Trials
Arun Sanyal, Virginia Commonwealth University

Developing Surrogate Endpoints – Lessons Learned from FNIH Osteoporosis Project
Tania Kamphaus, Foundation for NIH

Open Discussion
All attendees

What’s Next?

Wrap Up
Veronica Miller, Forum for Collaborative Research
Arun Sanyal, Virginia Commonwealth University
Becky Taub, Madrigal Pharmaceuticals


* Remote Participation